Aldesleukin Completed Phase 1 Trials for Neuroblastomas / High-risk Tumor / Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02130869A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
NCT00006480Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma
NCT00182650Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
NCT00058045Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
NCT00020462Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma
NCT00002687Interleukin-2 in Treating Patients With Mycosis Fungoides